Share Page:

Volume 28 , Issue 1
Winter 2014

Pages 6167

Antinociceptive Effects of Mirtazapine, Pregabalin, and Gabapentin After Chronic Constriction Injury of the Infraorbital Nerve in Rats

Kunihiro Nakai, MD, PhD/Aya Nakae, MD, PhD/Ryota Hashimoto, MD, PhD/Takashi Mashimo, MD, PhD/Ko Hosokawa, MD, PhD

PMID: 24482789
DOI: 10.11607/jop.1105

Aims: To clarify the antiallodynic effects of the α2-adrenergic receptor antagonist mirtazapine compared with those of gabapentin and pregabalin in a rat model of orofacial neuropathic pain. Methods: Mirtazapine (10, 30, and 100 μg), gabapentin (10, 30, and 100 μg), and pregabalin (3, 10, and 30 μg) were administered intrathecally to eight male Sprague-Dawley rats with orofacial neuropathic pain induced by chronic constriction injury of the infraorbital nerve that had been carried out 2 weeks previously. Stimulation using von Frey filaments (1.0 to 15.0 g) applied to skin innervated by the injured infraorbital nerve enabled the measurement of mechanical thresholds 0 to 180 minutes after drug injection. Time-course data for the dose-response effects were analyzed using two-way analysis of variance and the posthoc Tukey-Kramer multiple-comparison test. Results: Intrathecal administration of not only gabapentin and pregabalin but also mirtazapine reversed the lowered mechanical nociceptive thresholds produced by the nerve injury. The ED50 (95% confidence interval) was (in μg) 49.00 (39.7158.29) for mirtazapine, 54.84 (46.1263.56) for gabapentin, and 13.47 (11.2415.69) for pregabalin. Conclusion: Intraspinal administration of either mirtazapine, gabapentin, or pregabalin reverses the lowered facial mechanical thresholds produced in a rat model of trigeminal neuropathic pain. J Oral Facial Pain Headache 2014;28:6167. doi: 10.11607/jop.1105

Full Text PDF File | Order Article


Get Adobe Reader
Adobe Acrobat Reader is required to view PDF files. This is a free program available from the Adobe web site.
Follow the download directions on the Adobe web site to get your copy of Adobe Acrobat Reader.


© 2021 Quintessence Publishing Co, Inc

Current Issue
Ahead of Print
Author Guidelines
Submission Form
Quintessence Home
Terms of Use
Privacy Policy
About Us
Contact Us